Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nondependent Opioid Abuse, Episodic
Conditions
Nondependent Opioid Abuse, Episodic
Trial Timeline
Feb 1, 2011 → May 1, 2011
NCT ID
NCT01380093About Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride)
Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride) is a phase 1 stage product being developed by Pfizer for Nondependent Opioid Abuse, Episodic. The current trial status is completed. This product is registered under clinical trial identifier NCT01380093. Target conditions include Nondependent Opioid Abuse, Episodic.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01380093 | Phase 1 | Completed |